Surgical equipment market to reach $20 billion by 2025

As the number of minimally invasive surgical procedures grows, the value of the surgical equipment market is expected to escalate as well, to more than $20 billion by 2025.

A new report on the growth was released Jan. 2 by Grand View Research, a research and consulting company based in San Francisco. The surgical equipment market’s compound annual growth rate is expected to top 7 percent over the next decade to a total of $20.3 billion.

The report showed that surgical sutures and staplers were the highest grossing tools in the market in 2015. The market made $4 billion in 2015 and $3.9 billion in 2014.

Chronic diseases, neurological and cardiovascular problems are some of the biggest factors contributing to surgery increases. Additionally, obstetrics and gynecology held the largest market share because of the growing number of caesarean surgeries performed in 2015. There were more than one million caesarean deliveries performed in the U.S. in 2014, according to the Centers for Disease Control and Prevention.

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup